William Blair Initiates Coverage of Zura Bio with Outperform Rating

On July 8, 2026, William Blair initiated coverage on biotech firm Zura Bio (NASDAQ:ZURA) with an 'Outperform' rating. The decision was based on the potential for tibulizumab's dual mechanism of action to deliver differentiated efficacy in ongoing Phase 2 trials targeting hidradenitis suppurativa and systemic sclerosis.

By Jeff Lewis Tue, July 14, 2026 at 9:09 PM GMT+3 2 min read · Yahoo Finance · July 14, 2026, 18:09 UTC

William Blair Initiates Coverage of Zura Bio with Outperform Rating

Tickers: $ALNY

Topics: analyst ratings biotech clinical trials

Read the full article at Yahoo Finance

More World news

Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC